US 12,215,318 B2
Crispr enzymes and systems
Feng Zhang, Cambridge, MA (US); Aaron Smargon, Cambridge, MA (US); Neena Pyzocha, Cambridge, MA (US); David Benjamin Turitz Cox, Cambridge, MA (US); and Eric S. Lander, Cambridge, MA (US)
Assigned to The Broad Institute, Inc., Cambridge, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by The Broad Institute, Inc., Cambridge, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Apr. 23, 2018, as Appl. No. 15/960,064.
Application 15/960,064 is a continuation in part of application No. PCT/US2016/058302, filed on Oct. 21, 2016.
Claims priority of provisional application 62/376,382, filed on Aug. 17, 2016.
Claims priority of provisional application 62/376,367, filed on Aug. 17, 2016.
Claims priority of provisional application 62/296,548, filed on Feb. 17, 2016.
Claims priority of provisional application 62/245,270, filed on Oct. 22, 2015.
Prior Publication US 2019/0093107 A1, Mar. 28, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); C12N 9/22 (2006.01); C12N 15/10 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01); C12N 15/74 (2006.01); C12Q 1/6876 (2018.01); G16B 25/00 (2019.01); G16B 30/00 (2019.01); G16B 30/10 (2019.01); G16B 30/20 (2019.01)
CPC C12N 15/113 (2013.01) [C12N 9/22 (2013.01); C12N 15/102 (2013.01); C12N 15/111 (2013.01); C12N 15/63 (2013.01); C12N 15/74 (2013.01); C12Q 1/6876 (2013.01); G16B 25/00 (2019.02); G16B 30/00 (2019.02); G16B 30/10 (2019.02); G16B 30/20 (2019.02); C12N 2310/20 (2017.05); C12Q 2600/156 (2013.01)] 26 Claims
 
1. A non-naturally occurring or engineered composition consisting of
i) a Type VI-B CRISPR-Cas effector protein, and
ii) a Type VI-B CRISPR-Cas recombinant guide RNA,
wherein the recombinant guide RNA comprises, from 5′ to 3′ orientation, a) a heterologous guide sequence that is capable of hybridizing to a target RNA sequence, and b) a direct repeat sequence,
whereby there is formed a CRISPR complex comprising the Type VI-B CRISPR-Cas effector protein complexed with the guide sequence that is hybridized to the target RNA sequence, and wherein the Type VI-B CRISPR-Cas effector protein and Type VI-B CRISPR-Cas guide RNA do not naturally occur together.